In the News
The sites below may link you to other sites not under the control of Tengion, and you acknowledge that Tengion is not responsible for the accuracy, copyright compliance, legality, decency, or any other aspect of the content of such sites. The inclusion of such a link does not imply endorsement of the site by Tengion or any association with its operators.
Hot Technology That Could Change Health Care [Excerpted]
August 27, 2008
By Maureen Farrell
Advances in health care run the gamut from mind-boggling medicines to simple Web solutions that, if adopted, could slice huge slabs of fat from a bloated system.
If you think that stuff is straight out of Star Trek, how about "growing" new organs from the very patients that need them? Launched in 2004, Tengion, based in East Norriton, Pa., aims to do just that.
The process: A doctor takes a tissue sample from a diseased organ and sends it to Tengion's facility. There, the cells responsible for growth of new tissue are reproduced in a biodegradable "scaffold" made in the shape of the diseased portion of the organ. Several weeks later, surgeons implant the new organ/scaffold structure, leaving the patient's body to absorb the new organ and excrete the scaffold. Unlike those who receive organ transplants, Tengion's patients, in theory, won't need to be on a lifetime regimen of anti-rejection medicine.
So far, the company has invented a way of making a "neo-bladder" based on a patient's own tissue, and has filed for 70 patents covering the entire process. It plans to eventually move into manufacturing other organs and tissues, including kidneys, blood vessels, hearts, livers and nerves.
Tengion has already raised $150 million in total financing from the likes of Bain Capital, Johnson & Johnson Development Corporation (the consumer giant's VC arm), Oak Investment Partners and Quaker BioVentures. Not that success is right around the corner--the FDA won't approve the process until early next decade, says Gary Sender, Tengion's chief financial officer.
Then there's the whole push toward truly personalized medicine, which could fundamentally alter the way diseases are diagnosed and treated. Until now, doctors have relied on the law of averages: Clinical drug trials yield data on how many people are helped by a particular treatment; if the success rate is high enough, that treatment gets the nod.
But as the human genome is better understood, it's becoming apparent that diseases like cancer can be treated in specific ways, based on a patient's individual genetic code. "Nothing should cause us to expect that one person's cancer or arthritis or heart disease is like other patients," says Brook Byers, partner at the Menlo Park, Calif. venture giant Kleiner Perkins Caulfield & Byers. "Standardized treatments will shift to personalized and tailored ones with better outcomes and lower costs." Personalized medicine has been Kleiner Perkins' primary area of investment for its life sciences division.
Blood Vessels Made From Human Adult Stem Cells Grown in Mice [Excerpted]
July 18, 2008
By Rob Waters
Stem cells drawn from the blood system of adult humans or the umbilical cord blood of newborns, injected into mice, formed viable vessels that may one day deliver oxygen-rich blood to damaged organs, researchers said.
Unlike other experiments that have coaxed adult cells to perform new functions, the Harvard team didn't perform any genetic manipulation, said Joyce Bischoff, an associate professor at Harvard and Children's Hospital Boston. Because damaged heart tissue or festering wounds need blood and oxygen quickly to heal, "our goal is to speed it up to form blood vessels within one or two days," Bischoff said.
The advance could propel the emerging field of tissue engineering, which seeks to use stem cells and scaffolds to build replacement tissues and organs for people with various conditions. One closely held company, Tengion, based in East Norriton, Pennsylvania, is testing synthesized bladders in human trials and developing ways to create blood vessels and kidneys.
Tengion plans human tests of bladder replacement in '09 [Excerpted]
June 27, 2008
by John George
EAST NORRITON -- Tengion Inc. is getting ready to take its next leap in the field of regenerative medicine.
Now, Tengion is conducting preclinical studies of an entire, fully functional bladder -- also grown in the lab from a patient's own cells. The company hopes to begin testing its Neo-Bladder Replacement product in humans next year.
"This is the next generation in our bladder technology," said Gary Sender, chief financial officer.
Sender said the company's Neo-Bladder Replacement is being developed for bladder cancer patients whose entire bladder is removed -- a surgery known as a cystectomy -- as part of their treatments.
Working bladders grown from progenitor cells [Excerpted]
May 19, 2008
By Anthony J. Brown, MD
Months after being implanted into research animals, "neo-bladders" created from progenitor cells appear to function much like natural bladders, researchers have shown. This is the "first time a complete internal organ has been regenerated and shown to grow, develop normal or near-normal function, and support life for an extended period of time," Dr. Timothy Bertram told Reuters Health from the annual meeting of the American Urological Association in Orlando, Florida.
Tengion is Hopeful as Its Full Size Neo-Bladders Do Well in Animal Models [Excerpted]
May 19, 2008
Tengion, a company out of East Norriton, PA, has successfully grown full size replacement bladders in large mammal models, helping pave the way for the company to receive FDA clearance to initiate clinical trials on humans in 2009. The company says that the results from a preclinical trial show that its product, known as Tengion Neo-Bladder Replacement™, is structurally similar to native bladders by six months.
Replacement Bladder Grown From Body's Own Cells [Excerpted]
'Neo-organ' from intestinal tissue could offer therapy option for cancer patients
May 18, 2008
Using regenerative medical techniques, it may be possible to create replacement bladders for people who've had their bladder removed due to cancer. Replacement bladders made from intestinal tissue have proven successful but can cause a number of complications, such as chronic urinary retention, hematuria and infection, according to the researchers from Tengion Inc., in Winston-Salem, N.C.
Replacement Bladder Grown From Body's Own Cells [Excerpted]
'Neo-organ' from intestinal tissue could offer therapy option for cancer patients
May 18, 2008
U.S. Department of Health and Human Services
Using regenerative medical techniques, it may be possible to create replacement bladders for people who've had their bladder removed due to cancer. Replacement bladders made from intestinal tissue have proven successful but can cause a number of complications, such as chronic urinary retention, hematuria and infection, according to the researchers from Tengion Inc., in Winston-Salem, N.C.
Current Regenerative Medical Techniques Hold Great Promise For Bladder Regeneration[Excerpted]
May 18, 2008
American Urological Association News
The results of a new study, conducted in large mammals, presented at the May 2008 Annual Scientific Meeting of the American Urological Association (AUA), suggest that this process could result in a regenerated bladder with similar characteristics of the native bladder and without the risks associated with a donated organ or other undesirable outcomes associated with current surgical interventions.
Current Regenerative Medical Techniques Hold Great Promise For Bladder Regeneration [Excerpted]
May 17, 2008
Bladder regeneration via a neo-bladder replacement may prove to be effective in humans. The results of a new study, conducted in large mammals, presented May 15 at the 103rd Annual Scientific Meeting of the American Urological Association (AUA), suggest that this process could result in a regenerated bladder with similar characteristics of the native bladder and without the risks associated with a donated organ or other undesirable outcomes associated with current surgical interventions.
Growing a replacement organ for a patient using his or her own cells presents a new option. After a bladder biopsy is obtained from a patient, bladder progenitor cells are grown in culture and seeded on a biodegradable bladder-shaped scaffold made from collagen and/or polyglycolic acid. The neo-organ is then implanted into the patient.
Europeans give special status to Tengion bladder [Excerpted]
April 2, 2008
By Linda Loyd
Tengion Inc., East Norriton, said European regulators had designated its regenerative bladder, made from a patient's own cells, as an "orphan medicinal product." The status, which can speed the time to approval and reduce certain costs, is designated when experimental products meet a medical need for which there are not similar products.
Tengion neo-bladder gets orphan status in Europe [Excerpted]
April 1, 2008
The European Medicines Agency and the European Commission on Tuesday designated Tengion Inc.'s experimental "neo-bladder" augment as an orphan medicinal product for the treatment of spina bifida.
The designation qualifies Tengion of East Norriton, Pa., for EMEA regulatory incentives, including eligibility for protocol assistance and possible exemptions or reductions of certain regulatory fees.
Paving A Path To A Regenerative Medicine Industry [Excerpted]
A Conversation With Tengion CEO Steven Nichtberger
The Gray Sheet, Volume 33 Number 042
Tengion is not a device firm. It is not a biotech or drug company either, although CEO Steven Nichtberger says his company needs to draw on the models of each.
No, Tengion describes itself as a regenerative medicine company. It makes "neo-organs."
Last year, the East Norriton, Pa.-based company's product drew worldwide attention when researchers at the Wake Forest Institute for Regenerative Medicine, lead by Anthony Atala, M.D., reported results from seven bladder disease patients implanted with a partially formed bioengineered bladder made from a biodegradable scaffold and the patients' own cells ("The Gray Sheet" April 10, 2006, p. 15).
Typically, these patients would be treated with a procedure involving part of their bowel being grafted onto their bladder, which comes with significant adverse side effects.
Emerging Drug Developer: Tengion [Excerpted]
October 18, 2007
By John Carroll
For most up-and-coming biotech companies, just getting a therapeutic candidate through a proof-of-concept trial and into a licensing deal is a big enough challenge to consume all of their planning skills. For Tengion, though, the bar has been raised significantly higher.
Two small mid-stage trials for Tengion's neo-bladder--new bladders grown from the seeds of a patient's cells to replace defective bladders in children with spina bifida and spinal injuries--are being mounted as the company is putting the finishing touches on a manufacturing facility that can do all the planting and harvesting of new organs.
New Procedure Could Improve Bladders in Spinal Cord Patients
October 1, 2007 - KYW News Radio
Regenerative Medicine Focus of Conference in Winston-Salem
The Business Journal of the Greater Triad Area - Friday, September 21, 2007
by Matt Evans
The Business Journal
Lab to Limb: Clinical Applications of Regenerative Medicine[Excerpted]
August 2007 | Al Staropoli | American Association of Blood Banks (AABB) News
The bladder developed by Atala and his colleagues has been commercialized by Tengion. Results of Phase II trials, in which the bladder will be tested in 20 patients, are expected in 2008.
This is groundbreaking work because it will demonstrate in principle that this approach has merit and can help these types of patients," said Stephen Badylak, MD, PhD, director of the Center for Pre-clinical Testing at the McGowan Institute for Regenerative Medicine at the University of Pittsburgh and an adjunct professor at Wake Forest University.
Regenerative Medicine Enters Realm of Reality: Market Estimated to Have $500 Billion Potential [Excerpted]
April 2007 | Nina Flanagan | Genetic Engineering & biotechnology News
The idea of growing an organ from one's own cells or healing spinal cord injuries with cells transformed from embryonic stem cells used to be considered fodder for science fiction movies, but no more. Companies are not only developing technologies that can do exactly that, but these methods provide real potential to cure certain conditions and diseases.
According to "2020-A New Vision: A Future for Regenerative Medicine", from the U.S. DHHS, regenerative medicine has the potential to exceed $500 billion within the next 20 years.
Tengion has initiated what it claims is the first Phase II trial for the approval of a regenerated human organ. The urinary neo-bladder will be tested in 10 children with spina bifida who have failing bladders that predispose them to kidney failure.
Neo-organ replacement firm begins clinical trials [Excerpted]
01/05/07 | Linda Loyd | The Philadelphia Inquirer
Tengion Inc., a Montgomery County start-up developing replacement organs, announced today it has begun enrolling patients in a clinical trial that will implant new bladders in children whose own bladders are damaged due to spina bifida.
The 12-month study will determine the safety and effectiveness of Tengion's neo-bladder in 10 children, using the patient's own healthy cells which are grown on a biodegradable scaffold in a lab and then surgically implanted in the body where it continues to grow.
Tengion expects final data from the study in mid-2008. If the patient outcomes prove promising, the company hopes to have the first bladders commercially available by the end of the decade for children with spina bifida and adults with spinal–cord injuries.
With thousands of patients in America waiting for organ transplants, the prospect of creating replacement organs, using a patient's own cells, holds enormous potential. About one in every 2,000 U.S. children is born with spina bifida, which over time can cause failing bladders, kidney damage and, ultimately, kidney failure, Tengion said.
"The current treatment options for patients with bladder failure have been unchanged for decades," said David Joseph, a physician involved in the study at the University of Alabama. "This Tengion-sponsored trial represents a new approach that, if successful, could represent an exciting alternative" to medical procedures used in the past.
Tengion Replacement Bladder Enters Phase II [Excerpted]
01/08/07 | Dow Jones Venture Wire
Tengion Inc., an East Norriton, Pa., regenerative-medicine company backed with $89 million from the likes of Bain Capital Ventures and Johnson & Johnson Development Corp., has placed its lead product into Phase II clinical trials, a replacement bladder for spina bifida patients.
Tengion develops replacement organs by isolating and multiplying a patient's own progenitor cells and placing them into an organ-shaped scaffold, and then surgically implanting the "neo-organ." In this case, it isolates and expands urothelial and smooth-muscle cells and seeds a biodegradable scaffold to create a neo-bladder that is individualized for each patient. The replacement bladder is surgically implanted onto the patient's failing bladder. Ultimately, Tengion hopes to grow replacement organs to order for individual patients.
This year Tengion also expects to launch a Phase II study to grow replacement bladders for adults with spinal cord injury. Tengion's other backers include Quaker BioVentures, L Capital Partners, Scheer & Co., Oak Investment Partners and Healthcap Venture Capital.
Tengion moves forward with plan to grow new bladders [Excerpted]
01/05/07 | Philadelphia Business Journal
Tengion Inc. has initiated a phase-II multicenter clinical study for its "neo-bladder," a functioning organ created from a patient's own tissues.
The study is being conducted in pediatric patients with spina bifida who have failing bladders that predispose them to a risk of kidney failure and incontinence, even when they receive optimal medical therapy.
The East Norriton, Pa., company's neo-bladder construct is based on nearly two decades of research conducted at Tengion, the Harvard Medical School's Children's Hospital Boston and the Massachusetts Institute of Technology.
The neo-bladder constructs for the patients in this study are being developed at the Tengion pilot manufacturing facility in East Norriton. [The neo-bladder] is designed to harness the body's inherent regenerative capabilities resulting in an improved bladder that integrates with the patient's body as the scaffold degrades.
Alum: Help patients and turn a profit as well [Excerpted]
10/19/06 | Mara Wishingrad | DailyPennsylvanian.com
Can't decide whether to go into science or business? Steven Nichtberger has made a career in both.
Nichtberger, an alumnus of both Wharton and the College and the founder of Tengion, Inc., spoke last night in Huntsman Hall about "opportunities and challenges for the scientist-business leader."
Tengion, the company Nichtberger co-founded, is developing "neo-bladders," functional replacement bladders that come from a patient's own cells.
Nichtberger said he founded Tengion because "it fulfilled [his] dream of transforming health care for some patients," a dream he has had since his brother's death.
Nichtberger gave a brief history of the relationship between science, medicine and business.
In the 1960s, scientific research was funded by the government, and there was little interaction with industry, he said.
But during the 1980s and 1990s, the two areas drew closer together.
He said this convergence created issues that "a scientist alone or a businessman alone cannot mitigate," such as potential conflicts between profits and patients.
Tengion raises $50 million
8/9/2006 | Catherine Shaffer | Bioperform.com
Tengion, Inc., King of Prussia, Pa., has received $50 million in series 'B' financing for the development of their autologous neo-bladder construct. By licensing the neo-bladder technology developed at Harvard, Tengion has made itself a world leader in regenerative medicine. Also, uniquely, Tengion is able to base their business strategy on previous clinical studies done by the Harvard scientists. Although these studies did not fulfill FDA requirements for marketing, they offer a great deal of confidence in the eventual results of the approval process. Very few early stage biotech companies are able to start with a product that has already been through basic clinical testing.
Tengion's neo-bladder addresses a need among children with spina bifida, adults with spinal cord injuries, patients with bladder cancer, and other patients who have lost their bladders and need a replacement. Previously, grafts have been made using the bowel, but this has not been a wholly satisfactory treatment. The neo-bladder is custom-made for each patient, starting with a biopsy from the diseased or damaged bladder. The bladder cells grow on a collagen and polyglycolic acid scaffold, forming a three-dimensional replacement organ.
Gary Sender, Tengion's Chief Financial Officer, says, "There was significant preclinical and clinical experience using our technology done by our founding scientist at Harvard, but it was not done under an FDA sponsored program. Tengion is repeating both the preclinical and clinical work, collaboratively with the FDA...we have an interesting profile as an early stage life sciences company. It's very rare that a lead product already has human clinical experience. It's because of that fact that we've been able to raise capital from very prestigious venture capitalists, as well as hiring a leadership team with extensive experience and accomplishments behind them."
Tengion expects to submit an IND to seek approval to begin human clinical trials, and then start those trials before the end of the year. "We will begin with phase II trials. Phase I trials are done with healthy volunteers. This type of technology does not lend itself to finding volunteers who are willing to have their bladders replaced."
A Tissue Engineer Sows Cells and Grows Organs [Excerpted]
7/11/06 | Ann Parson | New York Times
"In April, when the two-year-old institute that Dr. [Anthony] Atala directs for Wake Forest's School of Medicine moved into some 50,000 square feet of space in the Piedmont Triad Research Park, it became one of the world's largest research facilities dedicated to regenerative medicine, a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells."
"At the institute, he and more than 80 colleagues are working on tissue replacement projects for practically every body part - blood vessels and nerves, muscles, cartilage and bones, esophagus and trachea, pancreas, kidneys, liver, heart and even uterus."
"In the long term, the scientists hope, patients may no longer have to wait on the national transplant list "for someone to die so they can live," as Dr. Atala puts it. Organs could be tailor-made for people."
"Dr. Atala leaves the job of getting the bladder replacements to the clinic to Tengion, a company established in 2003 that was his institute's first corporate partner. Tengion says it hopes to receive Food and Drug Administration approval by the end of the year for a clinical trial."
Developer of replacement organs raises $50M [Excerpted]
6/27/06 | Linda Loyd | The Philadelphia Inquirer
"Tengion Inc., a King of Prussia start-up developing replacement organs, such as bladders, announced today it has raised $50 million in a recently completed second equity financing round."
"The latest financing was led by Bain Capital LLC, of Boston, and Quaker BioVentures, of Philadelphia. The previous investors - Oak Investment Partners, Johnson & Johnson Development Corp., HealthCap and L. Capital Partners - also participated in the round."
"Tengion plans to use the funds for human clinical trials to advance development of its lead product, the bladder, to be used in patients with spina bifida and spinal cord injuries."
"The funds will also be used to develop Tengion's 45,000-square-foot manufacturing facility in East Norriton, Montgomery County, and to advance its product pipeline."
"The technology, which holds promise for other organs, including the heart, kidney, pancreas and liver, was developed by Atala and colleagues formerly of Children's Hospital of Boston and now Wake Forest University Institute for Regenerative Medicine."
Tengion Raises $50M To Build A Better Bladder [Excerpted]
6/27/06 | Jonathan Matsey | Dow Jones Venture Wire
"Organ regeneration company Tengion Inc. said that it has raised $50 million in Series B financing to progress its artificial bladder trials and manufacturing infrastructure. The company plans to do its manufacturing by itself, with no partner in the U.S."
"Tengion develops artificial bladders outside of the body using the patients own urothelial and muscle cells to construct a new organ for implantation."
"One of the key value drivers is our ability to make customized organs for each patient," [Tengion CFO Gary] Sender said, adding that the company is planning not to use a business partner in the U.S. market.
Tengion closes $50 million Series B [Excerpted]
6/27/06 | George White | The Daily Deal
"Regenerative medicine startup Tengion Inc. added another $50 million to its coffers on Monday, June 26, as the company announced the closing of its Series B funding."
" When Tengion began animal testing in summer 2004, it already had more than 15 years of research behind its technology. "
Tengion raises $50M in round of financing
6/26/06 | John George | Philadelphia Business Journal
Bladders Built in the Lab [Excerpted]
4/04/06 | Sylvia Pagan Westphal | Wall Street Journal Online
Cells, Plastic Shell Combine To Make the Nearest Thing Yet To a Fully Man-Made Organ
"Doctors first took biopsies of each patient's bladder tissue to obtain the bladder's two key cell types -- the urothelial cells lining the inside and the muscle cells on the outer surface. Over several weeks these cells were multiplied in the laboratory. Meanwhile, the doctors built a customized three-dimensional shell of biodegradable polymer in the shape of a bladder. Then they added the patient's cells to the shell -- first the inner layer, then the outer muscle layer -- mimicking the order in which the cells coexist in a real organ."
"Once enough cells attached themselves, the new bladder was sutured into the patient's defective bladder. To nurture the new organ, the scientists wrapped some of the patients' bladders with a blood-rich tissue called the omentum, which is present in people's abdominal cavities."
"The engineered bladder also remains an experimental device, and more clinical trials must be done before it can be widely available to people."
"Tengion Inc., a closely held company in King of Prussia, Pa., was founded in 2003 to commercialize the technology. Dr. Atala is one of the founders. According to Chief Financial Officer Gary Sender, the company is discussing trial design with the FDA and hopes to market the engineered bladder by the end of the decade."
An organ-implant first [Excerpted]
4/4/06 | Linda Loyd
"The technology, which holds promise for other organs, including the heart, kidney, pancreas and liver, was developed by pediatric urologist Anthony Atala and colleagues formerly of Boston Children's and now Wake Forest University Institute for Regenerative Medicine, according to the April 4 online edition of the Lancet[*], a British medical journal. Atala and his team are able to design an organ from scratch outside the body using a patient's cells and to surgically implant it in the body where it continues to grow. 'This is the first time a complex replacement organ has been put into a human designed from the person's own cells outside the body,' Atala said in a telephone interview."
"The technology has been licensed to a King of Prussia start-up firm, Tengion Inc., which plans to submit an application to the Food and Drug Administration by midyear and to begin its first clinical trials before the end of the year, said chief financial officer Gary Sender. If all goes well, Tengion hopes to have, by the end of the decade, the first bladders commercially available to children with dysfunctional bladders."
"The science behind Tengion was developed over 16 years and licensed in late 2003 by a Connecticut life-sciences advisory firm, Scheer & Co., which founded Tengion in early 2004. Tengion's management team, led by chief executive officer Steven Nichtberger, former head of global marketing for Merck & Co. Inc., has raised $39 million in venture capital and is in the process of raising 'a minimum' of $35 million more, said Sender, the company's CFO. The firm, which has 50 employees, recently leased 45,000 square feet in a warehouse on Germantown Pike and Potshop Lane in East Norriton, Montgomery County, and plans to build a commercial manufacturing plant and locate its corporate offices there. Tengion's science and technology operations are in Winston-Salem, N.C., where the company's two dozen scientists work closely with Atala. Tengion has built a a pilot plant in North Carolina, where the neo-bladders will initially be made for clinical trials."
"'It's groundbreaking science,' Sender said. 'Tengion is working with the Food and Drug Administration to try to bring this technology to patients.'"
Straight Out of Science Fiction: Organs Engineered in a Lab [Excerpted]
4/3/06 | Joy Victory, ABC News
"Dr. Anthony Atala, the director of the Institute for Regenerative Medicine at Wake Forest University in North Carolina, reports in tomorrow's issue of the medical journal The Lancet* about the...procedure."
"Atala was unavailable for comment, but Gary Sender, chief financial officer of the bio-technology firm Tengion, explained how it worked. His firm is developing the 'neo-bladder' technology and seeking approval from the Food and Drug Administration to further test it in humans, including adults."
"Eventually, tissue engineering technology could even replace organ transplants, Sender said."
"'The technology uses...cells that come from the patient,' he said. 'One of the great advantages is that there's no risk for rejection.'"
*The technology involved in the clinical experience described in The Lancet article is investigational. Further investigation of the safety and efficacy of the technology in clinical trials is necessary before it is submitted to FDA for review and consideration for approval.
Multimedia
Podcast
Interview with Steven Nichtberger, President and CEO after speaking on a Regenerative Medicine Panel at the Dow Jones VentureWire Healthcare Innovations Conference in September 2006.
Researchers Grow New Bladders Outside of the Body [Excerpted]
4/4/06 | Joanne Silberner | NPR
"Morning Edition, April 4, 2006 - Surgeons have figured out how to grow an organ outside the body. The advance is owes a lot to one doctor who decided that rather than watch children born with malfunctioning bladders, he'd try to develop a way to create new ones for them. Joanne Silberner reports."
More Articles about Tengion
Rendell On Hand For Tengion Groundbreaking
April 19, 2006 | The Evening Bulletin
Tengion to grow in Pa.
April 18, 2006 | Philadelphia Business Journal
Organs to Order
March 9, 2006 | The Economist
Organ Creation: Research company opens Winston office to develop technology to make human bladders
February 11, 2006 | M. Paul Jackson | Winston-Salem Journal
Your Replacement Parts
September 19, 2005 | Linda Loyd | The Philadelphia Inquirer
Tengion Trying to Grow Human Organs
September 11, 2005 | John George | Philadelphia Business Journal
Scheer's Past Successes Draw Interest In Two New Endeavors
September 2005 | Tom Salemi | Dow Jones Venture Capital Analyst, Healthcare Edition
Tengion, Inc.: Engineering Autologous Replacement Organs
September 2005 | Nancy Dvorin | Start - Up
Tech Firm Tengion Plans Office
August 13 , 2005 | Paul Jackson | The Winston-Salem Journal
Articles about Regenerative Medicine
2020: A New Vision, A Future For Regenerative Medicine.
January 2005 | Washington DC.
Latest News
- July 23, 2008: Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
- June 30, 2008: Tengion CEO Dr. Steven Nichtberger Wins Ernst & Young Greater Philadelphia Entrepreneur Of The Year Award®
- June 12, 2008: Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration vs. Repair
- June 11, 2008: Tengion Named One of the Best Places To Work in Industry By the Scientist Magazine